BridgeBio price target raised to $100 from $55 at Goldman Sachs

Goldman Sachs raised the firm’s price target on BridgeBio (BBIO) to $100 from $55 and keeps a Buy rating on the shares. BridgeBio’s Q3 results highlighted strong commercial momentum for Attruby, with U.S. sales of $108.1M, exceeding estimates and reflecting a 40% increase in prescriptions since August, the analyst tells investors in a research note. Management cited growing share among newly diagnosed ATTR-CM patients and reiterated a 30%-35% target, supported by continued investment in awareness and diagnosis expansion. With topline results from the PROPEL 3 achondroplasia study expected in early 2026 and a deepening commercial pipeline, BridgeBio’s transition toward a multi-product, profitable biotech remains on track, offering further upside potential, the firm says.